Chongqing Chemdad Shines at CPHI China 2024 in Shanghai
From June 19 to 21, 2024, Chemdad participated in the 22nd CPHI China in Shanghai. At this grand event, Chemdad highlighted its innovative one-stop supply chain service platform for pharmaceutical and chemical products.
The 22nd CPHI China and the 17th PMEC China were held at the Shanghai New International Expo Centre from June 19-21, 2024. The event's theme was "Driving Pharmaceutical Innovation and Promoting High-Quality Industrial Development." The exhibition attracted over 3,500 companies from more than 150 countries and regions, covering a 210,000 square meter exhibition area and drawing over 90,000 domestic and international professional visitors.
During this grand event, Chemdad highlighted its innovative one-stop supply chain service platform for pharmaceutical and chemical products. Through its advanced online platform, Chemdad aims to provide a highly efficient, transparent, and reliable procurement experience for global customers sourcing active pharmaceutical ingredients (APIs), intermediates, fine chemicals, and specialty chemicals. Throughout the exhibition, Chemdad's booth attracted a large number of domestic and international visitors. The company's team engaged in deep and productive discussions with many new and existing customers, industry partners, and experts on topics such as market dynamics, technical challenges, and how digitalization is reshaping traditional supply chains.
Chemdad's Marketing Director stated that the exhibition provided an excellent opportunity to connect with global partners. The company has leveraged technological innovation and production capacity upgrades to build a product matrix in key therapeutic areas, enabling it to offer one-stop solutions. During the event, Chemdad reached preliminary cooperation agreements with several well-known pharmaceutical companies from Europe and Southeast Asia.
As the exhibition concluded, Chemdad not only showcased its core competencies but also gained clarity on key industry trends. Looking ahead, the company will continue to leverage its technological and quality advantages to deepen global collaborations and contribute to the high-quality development of the pharmaceutical industry.